Importantly, ASS1 loss has also been implicated in chemotherapeutic resistance in different tumors, including non-small cell lung cancer, ovarian cancer, and hepatocellular carcinoma [51, 53–58], suggesting ASS1 to be a vulnerable metabolic hub for the development of therapy resistance. This evidence concerns the gene ASS1 and non-small cell lung carcinoma.